Literature DB >> 15971273

The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries.

R Arjen Kramer1, Wilfred E Marissen, Jaap Goudsmit, Therese J Visser, Marieke Clijsters-Van der Horst, Arjen Q Bakker, Maureen de Jong, Mandy Jongeneelen, Sandra Thijsse, Harold H J Backus, Amy B Rice, William C Weldon, Charles E Rupprecht, Bernhard Dietzschold, Alexander B H Bakker, John de Kruif.   

Abstract

Antibody phage display technology was used to identify human monoclonal antibodies that neutralize rabies virus (RV). A phage repertoire was constructed using antibody genes harvested from the blood of vaccinated donors. Selections using this repertoire and three different antigen formats of the RV glycoprotein (gp) resulted in the identification of 147 unique antibody fragments specific for the RV gp. Analysis of the DNA sequences of these antibodies demonstrated a large variation in the heavy- and light-chain germ-line gene usage, suggesting that a broad antibody repertoire was selected. The single-chain variable fragment (scFv) antibodies were tested in vitro for RV neutralization, resulting in 39 specificities that neutralize the virus. Of the scFv clones, 21 were converted into full-length human IgG(1) format. Analysis of viral escape variants and binding competition experiments indicated that the majority of the neutralizing antibodies are directed against antigenic site III of the RV gp. The obtained specificities expand the set of human anti-RV antibodies eligible for inclusion in an antibody cocktail aimed for use in rabies post-exposure prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15971273     DOI: 10.1002/eji.200526134

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  30 in total

1.  Highly conserved protective epitopes on influenza B viruses.

Authors:  Cyrille Dreyfus; Nick S Laursen; Ted Kwaks; David Zuijdgeest; Reza Khayat; Damian C Ekiert; Jeong Hyun Lee; Zoltan Metlagel; Miriam V Bujny; Mandy Jongeneelen; Remko van der Vlugt; Mohammed Lamrani; Hans J W M Korse; Eric Geelen; Özcan Sahin; Martijn Sieuwerts; Just P J Brakenhoff; Ronald Vogels; Olive T W Li; Leo L M Poon; Malik Peiris; Wouter Koudstaal; Andrew B Ward; Ian A Wilson; Jaap Goudsmit; Robert H E Friesen
Journal:  Science       Date:  2012-08-09       Impact factor: 47.728

2.  Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus.

Authors:  Mark Throsby; Cecile Geuijen; Jaap Goudsmit; Arjen Q Bakker; Jehanara Korimbocus; R Arjen Kramer; Marieke Clijsters-van der Horst; Maureen de Jong; Mandy Jongeneelen; Sandra Thijsse; Renate Smit; Therese J Visser; Nora Bijl; Wilfred E Marissen; Mark Loeb; David J Kelvin; Wolfgang Preiser; Jan ter Meulen; John de Kruif
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  A novel ELISA for quantification of glycoprotein in human rabies vaccines using a clinically proven virus neutralizing human monoclonal antibody.

Authors:  Sunil Gairola; Manish Gautam; Satish Waghmare
Journal:  Hum Vaccin Immunother       Date:  2020-01-23       Impact factor: 3.452

Review 4.  Phage Display Libraries: From Binders to Targeted Drug Delivery and Human Therapeutics.

Authors:  Mouldy Sioud
Journal:  Mol Biotechnol       Date:  2019-04       Impact factor: 2.695

5.  Quantitative characterization of the B cell receptor repertoires of human immunized with commercial rabies virus vaccine.

Authors:  Pingsen Zhao; Sharula Guo; Zhixiong Zhong; Songtao Yang; Xianzhu Xia
Journal:  Hum Vaccin Immunother       Date:  2021-08-03       Impact factor: 4.526

6.  Use of the VH6-1 gene segment to code for anti-interleukin-18 autoantibodies in multiple sclerosis.

Authors:  Marina Tiumentseva; Vera Morozova; Aleksandr Zakabunin; Denis Korobko; Nadezhda Malkova; Maksim Filipenko; Nina Tikunova
Journal:  Immunogenetics       Date:  2016-01-07       Impact factor: 2.846

7.  A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo.

Authors:  John V Williams; Zhifeng Chen; Gabriella Cseke; David W Wright; Christopher J Keefer; Sharon J Tollefson; Ann Hessell; Amy Podsiad; Bryan E Shepherd; Pietro Paolo Sanna; Dennis R Burton; James E Crowe; R Anthony Williamson
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

8.  Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin.

Authors:  Nick S Laursen; Robert H E Friesen; Xueyong Zhu; Mandy Jongeneelen; Sven Blokland; Jan Vermond; Alida van Eijgen; Chan Tang; Harry van Diepen; Galina Obmolova; Marijn van der Neut Kolfschoten; David Zuijdgeest; Roel Straetemans; Ryan M B Hoffman; Travis Nieusma; Jesper Pallesen; Hannah L Turner; Steffen M Bernard; Andrew B Ward; Jinquan Luo; Leo L M Poon; Anna P Tretiakova; James M Wilson; Maria P Limberis; Ronald Vogels; Boerries Brandenburg; Joost A Kolkman; Ian A Wilson
Journal:  Science       Date:  2018-11-02       Impact factor: 47.728

Review 9.  Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy.

Authors:  Kristian Daniel Ralph Roth; Esther Veronika Wenzel; Maximilian Ruschig; Stephan Steinke; Nora Langreder; Philip Alexander Heine; Kai-Thomas Schneider; Rico Ballmann; Viola Fühner; Philipp Kuhn; Thomas Schirrmann; André Frenzel; Stefan Dübel; Maren Schubert; Gustavo Marçal Schmidt Garcia Moreira; Federico Bertoglio; Giulio Russo; Michael Hust
Journal:  Front Cell Infect Microbiol       Date:  2021-07-07       Impact factor: 5.293

10.  The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity.

Authors:  Ann R Hunt; Shana Frederickson; Toshiaki Maruyama; John T Roehrig; Carol D Blair
Journal:  PLoS Negl Trop Dis       Date:  2010-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.